What if one of the most talked-about longevity supplements, a molecule famous for extending healthspan in aging mice, had a hidden downside in the liver? A new study in Research suggests exactly that. Long-term alpha-ketoglutarate (AKG) intake caused fatty liver in healthy mice. The way it did so is a surprising chain of molecular events that few people taking the supplement have probably heard about.
This is a mouse study, and it is not a verdict on human safety. Even so, it asks an uncomfortable question about a supplement widely taken by healthy people.
Why AKG Became a Longevity Darling
Alpha-ketoglutarate is a central intermediate in the tricarboxylic acid (TCA) cycle, the metabolic engine that helps cells turn nutrients into energy. It also acts as a cofactor for enzymes involved in epigenetic regulation. In supplement form, often as calcium AKG (Ca-AKG), it has been marketed for anti-aging and performance benefits.
Much of the enthusiasm comes from earlier mouse work in which Ca-AKG was linked to improved healthspan and a reduction in frailty. Other reports have described antidiabetic and anti-obesity effects, mostly under pathological conditions such as diet-induced metabolic disease. In those settings AKG looked helpful.
The new study, from a team at Huazhong University of Science and Technology and collaborators in Wuhan, asked a question that has received much less attention. What happens when healthy animals take AKG for a long time? That is the situation of many real-world supplement users, who are often not sick at all.
The Finding: Fat Piling Up in the Liver
The researchers gave healthy mice AKG for an extended period, either mixed into their food or dissolved in their drinking water. Both routes produced the same result: markedly elevated hepatic triglyceride levels and steatosis, the medical term for fatty liver.
The cause was not simply more fat being made. AKG suppressed the activity of adipose triglyceride lipase (Atgl), the key enzyme that breaks down stored triglycerides. With that fat-burning machinery dampened, fat accumulated in liver cells.
The Molecular Chain of Events
The more interesting part of the paper is how AKG achieves this. The authors trace a multi-step pathway.
Step 1: Epigenetic change at Pck1. AKG reduced H3K4me3, a histone mark associated with active gene promoters, at the promoter of Pck1. Despite what one might expect from a lower activating mark, Pck1 transcription went up. Pck1 encodes phosphoenolpyruvate carboxykinase 1, a key metabolic enzyme.
Step 2: More lactate. Higher Pck1 activity promoted lactate production in the liver.
Step 3: Lactylation of Cidec. Lactate is not just a metabolic byproduct. It can be attached to proteins as a chemical modification called lactylation. Here it modified Cidec (cell death-inducing DNA fragmentation factor 45-like effector C), a lipid-droplet protein that inhibits Atgl.
Step 4: Protection from degradation. Normally the E3 ligase TRIM21 tags Cidec with ubiquitin, marking it for destruction. Lactylation interfered with this ubiquitination, so Cidec became more stable and accumulated.
Step 5: Atgl is restrained. With more Cidec around, Atgl activity was inhibited, triglyceride breakdown slowed, and fat built up.
The authors call this a "lactylation-ubiquitination crosstalk," in which one protein modification blocks another to alter protein stability and, ultimately, lipid metabolism.
Proof the Pathway Matters
The study did not rely on correlation alone. Hepatocyte-specific knockdown of either Cidec or Pck1 markedly reduced AKG-induced steatosis. Remove a key link in the chain and the fatty liver largely failed to develop, which is strong evidence that this pathway drives the effect.
How to Reconcile This With Earlier Lifespan Results
The obvious puzzle is how a compound that appeared to improve healthspan in mice can also promote fatty liver. There are several plausible ways to think about it, though the paper itself does not settle the question.
- Context matters. Benefits reported in disease models or aging cohorts do not necessarily carry over to young, healthy animals, and the reverse is also true.
- Dose and duration. Chronic, continuous exposure may tip metabolic pathways in ways that short or intermittent use does not.
- Tissue-specific trade-offs. A change that is neutral or helpful in one tissue or setting can be harmful in the liver, where lipid handling is tightly controlled.
The authors conclude that even AKG, a compound with established health benefits, may pose a risk of liver injury when used chronically in healthy mice. That is a caution about chronic use in healthy animals, not a claim that the earlier findings were wrong.
What This Study Does Not Show
It is worth being clear about the limits.
- Mice only. There are no human data here. Whether people taking AKG develop fatty liver is unknown from this work.
- Dose translation. Doses used in rodents do not map neatly onto supplement doses in people.
- Fatty liver is not liver failure. Steatosis is an early and often reversible state, though it can progress in some people.
- The mechanism is the novelty. The study's main contribution is identifying the Pck1–lactate–Cidec–TRIM21–Atgl axis, which may inform future research well beyond AKG.
The authors declared no competing interests.
Practical Takeaways
Who is affected? The people most relevant to this question are healthy adults taking AKG or Ca-AKG daily for months or years in pursuit of longevity or performance. People who already have fatty liver disease, metabolic syndrome, obesity, heavy alcohol use or elevated liver enzymes have more reason to be careful, though this study did not test those groups.
What to monitor. If you take AKG long-term, consider asking your doctor about routine liver tests such as ALT and AST, and about whether a metabolic panel or liver imaging makes sense given your risk factors. Tracking these markers over time is more informative than a single reading.
Talk to your clinician. Tell your doctor about all supplements you take, particularly if you use several at once or take medications processed by the liver.
Don't panic, but stay aware. A mouse study does not mean AKG is dangerous to humans. It does mean that "natural" and "metabolite found in the body" do not equal "risk-free at chronic supplemental doses." Human trials with liver endpoints would be the logical next step.
The Bigger Picture
The longevity supplement market often moves faster than the evidence. Promising results in aged mice can turn into mass-market products long before long-term safety in healthy humans is established. This study is a reminder that metabolic intermediates are active signaling molecules, and that chronic supplementation can reshape epigenetic marks, protein modifications and lipid handling in unexpected ways.
For now, the finding is a flag, not a verdict. It points to a specific, testable mechanism and gives researchers a clear target to look for in people.